VEGFmRNA and eNOSmRNA expression in immature rabbits with bleomycin-induced pulmonary hypertension GONG Fang-qi (~lS~) Objective: To investigate the evolution of pulmonary hypertension, the pathological changes of pulmonary arteries, and the expression of VEGFmRNA and eNOSmRNA of pulmonary arterial endothelial cells in immature rabbits treated with intratracheal bleomycin (BLM). Methods: Immature rabbits were divided into control and BLM group. Two and four weeks after intratracheal normal saline or BLM injection, the systolic, diastolic and mean pulmonary artery pressure (PASP, PADP, MPAP) were measured by micro-catheter; the pathological changes and the expression of VEGFmRNA and eNOSmRNA of endothelial cells in pulmonary arteries were evaluated by HE and in situ hybridization. Results: Two and four weeks after intratracheaI injection of BLM, the PASP, PADP and MPAP increased 53%, 49%, 52% in 2 weeks, and 43%, 89%, 56% in 4 weeks; the wall thickness increased and the cavity in middle and small pulmonary arteries became narrow: the Thickness Index (TI) and Area Index (AI) increased 25%, 14% in 2 weeks, and 22%, 24% in 4 weeks; the level of VEGFmRNA and eNOSmRNA expression decreased 46%, 43% in 2 weeks, and 43%, 51% in 4 weeks. There was no significant difference between 2 weeks and 4 weeks BLM groups. Conclusion: The pulmonary artery pressure was elevated, the thickness of wall increased and the cavity became narrow in middle and small pulmonary arteries, and the level of VEGFmRNA and eNOSmRNA expression in pulmonary arterial endothelial cells decreased in immature rabbits after 2 weeks and 4 weeks of intratracheal 4 U/kg BLM injection.
INTRODUCTION
Pulmonary hypertension is not rare in human with some heart and lung diseases. Chronic pulmonary hypertension leads to structural alterations of the lung vessels. The pathophysiology of this remodeling process is still poorly understood.
Furthermore, the structural damage of the lung * Project (No. 300528) supported by the Natural Science Foundation of Zhejiang Province, China vessels limits the clinical success of vasodilator treatment. Assuming genetic susceptibility, shear stress and inflammation are the principal pathogenetic factors involved in lung vessel remodeling (Voelkel and Tuder, 1995) , Vascular endothelial growth factor (VEGF) was first discovered as a potent and specific mitogen for endothelial cells (Ferrara and Henzel, ! 989) and a vascular permeability factor (Leung et al., 1989) and was found to play an important role in normal as well as pathological angiogenesis (Plate et al., 1992) . Nitric oxide (NO) has many important roles in vascular biology, including regulation of vascular tone and inhibition of platelet aggregation and leukocyte adherence (Faraci and Brian, 1994; Moncada and Higgs, 1993; Moncada et al., 1991) . NO is considered to be an important modulator in pulmonary hypertension by virtue of its antiplatelet effect and its vasodilatory and antiproliferative actions on pulmonary vascular smooth muscle cells (Garg and Hassid, 1989; Roberts et al., 1995; Heath, 1993; Radomski et al., 1987; Assender et al., 1991; deGraaf et al., 1992; Williams et al., 1992) . The main source of NO in normal vessels is endothelial nitric oxide synthase (eNOS). VEGF and eNOS have been demonstrated to be related closely with pulmonary hypertension.
Many studies showed that pulmonary hypertension could be induced by intratracheal injection of BLM in many animals (Phan et al., 1981; Snider, 1983; Michel et al., 1988) . In order to reveal the pathophysiology of pulmonary hypertension in immature animals, we investigated the evolution of pulmonary hypertension, the pathological changes of pulmonary arteries, and the expression of VEGFmRNA and eNOSmRNA of pulmonary arterial endothelial cells in immature rabbits treated with intratracheal bleomycin (BLM) injection.
METHODES

Animals
One month old rabbits were used in this study. Thirty three immature rabbits were randomly chosen to receive intratracheal injection of normal saline or BLM by tracheal puncture. This protocol resulted in the creation of 2 groups:
Control group: 14 immature rabbits treated with intratracheal injection of 0.2 ml/kg normal saline.
BLM group: 19 immature rabbits treated with intratracheal injection of 4 U/kg BLM (diluted by normal saline, 2 U/0.1 ml).
Experimental protocol
Hemodynamic studies were conducted 14 days (Control group 8, BLM group 10) or 28 days (Control group 6, BLM group 9) after rabbits were randomly assigned to receive intratracheal injection of normal saline or BLM. After the rabbits were anesthetized with intraperitoneal injection of pentobarbital (40 mg/kg), a catheter (Hydrocath 20 G/1.1, Flow rate 13 ml/min, OHMEDA, U.K.) was inserted through the right jugular vein into the pulmonary artery for measurement of systolic pulmonary artery pressure (PASP), diastolic pulmonary artery pressure (PADP) and mean pulmonary artery pressure (MPAP). These hemodynamic variables were measured with a pressure transducer connected to a monitor (Hewlett-Packard). After completion of the above measurement, cardiac arrest was induced by draining blood through the catheter. The lungs were excised, dissected free, and washed in 4 ~ normal saline and 4 ~ 0.1 mol/L PBS+DEPC.
Morphometric Analysis of Pulmonary Arteries
Paraffin sections 4 ~tm thick were obtained from the low region of the left lung and stained with hematoxylin and eosin for examination by light microscopy. The external and internal diameter, and the vessel area and vessel cavity area were measured in middle and small pulmonary arteries per lung section. For each artery, the arterial well thickness was expressed as follows: Thickness Index (TI)=l-internal diameter/external diameter. The arterial wall area was expressed as follows: Area Index (AI)=l-vessel cavity area/vessel area.
In situ hybridization
The VEGFmRNA and eNOSmRNA expression of endothelial cells in pulmonary arteries were evaluated by in situ hybridization which was performed as kit described in the VEGF kit.
The VEGF probe sequences of oligonucleotides (VEGF kit, Boster Co., Cat. NO. MK1142) were 5'-TGGGACCACTTGGCATGGTGGAGGT-AGAGC-3' for oligonucleotide 1, 5'-GGGTACTCCTGGAAGATGTCCACCA-GGGTC-3' for oligonucleotide 2, 5'-CTGCAAGTACGTTCGTTTAACTCAA-GCTGC-3' for oligonucleotide 3.
The eNOS probe sequences of oligonucleo-
